VivoSim Labs Announces Pricing of Up to \$4 Million Public Offering: Key Details for Investors

Overview

VivoSim Labs, Inc. (Nasdaq: VIVS), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety testing, has announced the pricing of a significant public offering. The offering is structured as a best-efforts deal, with the potential to raise up to \$4 million in total, comprising an initial closing of \$3 million and a second closing of \$1 million, subject to certain conditions.

Key Points of the Offering

• Initial Closing: \$3 million funded, expected to occur April 1, 2026.
  – Issuance and sale of 286,557 common shares and 2,345,022 pre-funded warrants.
  – Subscription price: \$1.140 per common share, \$1.139 per pre-funded warrant.
• Common Warrants: 3,947,369 common warrants to purchase up to 150% of the aggregate number of shares (common stock or pre-funded warrants) sold at Initial Closing.
  – Exercise price: \$1.710 per share.
  – Warrants are immediately exercisable and expire five years from issuance.
• Pre-funded Warrants: Exercise price of \$0.001 per prefunded warrant share, immediately exercisable, expire when exercised in full.
• Second Closing: Up to \$1 million additional funding on the 30th day following the Initial Closing.
  – Subject to satisfaction of conditions, including minimum closing price and average trading volume.
  – Additional issuance of common stock or pre-funded warrants and common warrants (up to 150% of aggregate shares sold at Second Closing).
• Lead Investor: New York-based single family office leads the subscription.
• Placement Agent: Joseph Gunnar & Co., LLC serves as exclusive placement agent.
• Regulatory Details: All securities are being offered pursuant to an effective registration statement on Form S-1 (File No. 333-294716) with the SEC, declared effective on March 31, 2026.

Important Information for Shareholders

• Potential Dilution: The issuance of new shares, pre-funded warrants, and common warrants represents a substantial potential dilution to existing shareholders. The total number of new securities could significantly increase the company’s outstanding shares if warrants are exercised.
• Price Sensitivity: The offering price (\$1.140 per share) and warrant exercise price (\$1.710 per share) may establish new reference points for the stock’s valuation. Additionally, the conditions for the second tranche, such as minimum closing price and trading volume, could affect share price volatility.
• Market Risks: The completion of the second closing is not guaranteed and is subject to market conditions. Any failure to meet closing conditions may impact investor sentiment and share price.
• Forward-Looking Statements: Management cautions that completion of the public offering and satisfaction of conditions for the additional tranche are not assured. Investors should review risk factors in the company’s SEC filings, including the Annual Report on Form 10-K and Registration Statement on Form S-1.
• Regulatory Momentum: VivoSim anticipates increased adoption of its NAM technology following the FDA’s April 2025 announcement favoring non-animal testing methods. This regulatory change could accelerate business growth and positively impact shareholder value.

Company Background

VivoSim Labs, Inc. is a pharmaceutical and biotechnology services company specializing in 3D human tissue models for liver and intestinal toxicology. The company is positioned to benefit from regulatory shifts toward non-animal testing methods, potentially driving demand for its NAMs solutions. VivoSim operates from San Diego, California.

For further information, investors are encouraged to review the company’s filings on the SEC’s website or contact Investor Relations at [email protected].

Potential Impact on Share Price

• The public offering could be a major share price mover, due to both dilution risk and potential funding for accelerated growth. The pricing and terms set a new valuation benchmark that could influence trading dynamics in the near and medium term.
• Completion of the second tranche is uncertain, and any update regarding its status could materially affect investor confidence and stock performance.
• Increased regulatory support for NAMs may drive future revenue growth, which could be positively reflected in the share price, especially as new contracts or partnerships are announced in response to FDA policy changes.

Disclaimer

The information provided herein is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities. The completion of the public offering and the satisfaction of conditions for the additional tranche are subject to risks and uncertainties. Investors should not place undue reliance on forward-looking statements and are advised to consult the company’s filings with the SEC for a comprehensive discussion of risk factors. This article should not be construed as financial advice.

View VivoSim Labs, INC. Historical chart here